Show Notes
About the Episode In today's episode, Dr. Brendan Byrne is interviewing Lisa Maks, a Diabetes Clinical Nurse Specialist at Providence Health Care with 38 years in nursing, 22 of them in diabetes care. She is an Adjunct Professor at the University of British Columbia and serves on the Diabetes Canada Clinical Practice Guidelines committee. She is also a LifestyleRx patient, which gives her a rare view from both sides of the clinic.
About the Guest Lisa Maks is a Diabetes Clinical Nurse Specialist at Providence Health Care with 38 years in nursing, 22 of them in diabetes care. She is an Adjunct Professor at the University of British Columbia and serves on the Diabetes Canada Clinical Practice Guidelines committee. She is also a LifestyleRx patient, which gives her a rare view from both sides of the clinic.
About The Path Podcast
The Path is about simple strategies for better metabolic health. We break down metabolic disease, prediabetes, and type 2 diabetes through patient FAQs, better health decisions, and honest interviews with patients and the physicians who treat them.
Learn More About LifestyleRx: https://lifestylerx.io/
Ask us a video question! https://ask-a-question.lifestylerx.ca
Episode 112 | The Path Podcast
Timestamps 0:00 Intro 1:03 Welcome & Lisa's background 3:12 Obesity and weight cycling 5:12 How she discovered LifestyleRx 7:01 – First impressions of the program 10:52 – Consistency over intensity 14:49 – How physiology shapes behavior 15:59 – All-or-nothing mindset and food noise 18:19 – Outcome-based vs. process-based goals 20:08 – Measuring success beyond the scale 23:59 – Listening to your physiology 26:06 – The Amundsen vs. Scott metaphor 28:17 – Deciding to start a GLP-1 32:06 – How GLP-1 quieted food noise 34:26 – Obesity as a dysregulated system 36:26 – Facing the "cheating" stigma 37:53 – Willpower and hedonistic behavior 41:03 – Our evolutionary food mismatch 44:49 – LifestyleRx's prevention mission 46:22 – Food quality and social determinants 50:07 – Dopamine and engineered foods 50:55 – "Lifestyle first" vs. "lifestyle next" 51:03 – Weight management as an ongoing practice 54:19 – Closing thoughts 54:45 - Outro
More from The Path from LifestyleRx
About the Episode For years, osteoarthritis was blamed on simple wear and tear, but new research points to inflammation and metabolic health as major drivers of joint pain. Dr. Maziar Badii explains how osteoarthritis is diagnosed, why weight loss and food choices can ease joint pain, and why exercise, even running, is rarely off limits. You will also hear how treatment works, from creams and pills to injections and joint replacement.
About the Episode As part of our late summer break, we're revisiting one of our favorite conversations from The Path archive. Most of us lose muscle as we age, and the tiny engines inside our cells, called mitochondria, get weaker too, which feeds insulin resistance and type 2 diabetes. In this episode, Dr. Mark Tarnopolsky explains how exercise, protein, and colorful foods help protect both, and why strength and endurance training each matter. He also shares how to check supplement claims, including a protein blend from his own company.
About the Episode You can develop serious liver scarring without ever drinking alcohol. Liver specialist Dr. Alnoor Ramji explains why fat in the liver deserves attention, how it connects to insulin resistance and type 2 diabetes, and which simple yearly blood test can flag liver damage early. You'll also learn which food and activity changes help, and why the liver has a strong ability to heal.
About the Episode Type 2 diabetes does not start when blood sugar rises. It starts years earlier, in the small cells of the pancreas that make insulin. Dr. Brendan Byrne talks with diabetes researcher Dr. Jim Johnson about whether too much insulin can come before insulin resistance, why many of these cells are tired rather than gone, and how rest, food choices, and exercise may help them recover.
About the Episode Some people diagnosed with type 2 diabetes have a slow, autoimmune form of diabetes called LADA, where the immune system attacks the cells that make insulin. Dr. Brendan Byrne and endocrinologist Dr. Tom Elliott explain how antibody testing works, what the newly approved drug teplizumab can and can't do, and why very low doses of Ozempic may help protect insulin-making cells. They also look ahead at the treatments that could arrive in the next five to ten years.